or Try an Advanced Search...

    Technical Analysis for VSTM - Verastem, Inc.

    Grade Last Price % Change Price Change
    C 4.12 -66.17% -8.06
    VSTM closed down 66.17 percent on Friday, May 24, 2024, on 37.66 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. The bears made the stock sink to a new 52-week low.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical VSTM trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    Fell Below 200 DMA Bearish 0.00%
    Fell Below 50 DMA Bearish 0.00%
    MACD Bearish Centerline Cross Bearish 0.00%
    MACD Bearish Signal Line Cross Bearish 0.00%
    New 52 Week Closing Low Bearish 0.00%
    New Downtrend Bearish 0.00%
    180 Bearish Setup Bearish Swing Setup 0.00%
    Expansion Breakdown Bearish Swing Setup 0.00%
    Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
    Older End-of-Day Signals for VSTM ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown 3 days ago
    2x Volume Pace 3 days ago
    1.5x Volume Pace 3 days ago
    3x Volume Pace 3 days ago
    10x Volume Pace 3 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    VSTM Chart by TradingView
    Basic chart:

    Profile

    Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The company's lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The company's product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Oncology Stem Cell Breast Cancer Ovarian Cancer Treatment Of Breast Cancer Signal Transduction mTOR Cancer Research Companion Diagnostic Metastasis Advanced Cancer Mesothelioma Advanced Cancers Cancer Stem Cell Cancer Stem Cells Mtor Inhibitors

    Is VSTM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 26 Verastem: A Shocking Drop On 'Positive' Data (Maintain Buy)
    May 26 Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade
    May 24 Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
    May 24 What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
    May 24 Sector Update: Health Care Stocks Advance Pre-Bell Friday
    May 24 ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
    May 24 Verastem whipsaws after updates for cancer drug combo
    May 24 Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
    May 24 Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
    May 23 Verastem stock rallies on positive data for pancreatic cancer drug combo
    See more VSTM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.18
    52 Week Low 4.02
    Average Volume 517,549
    200-Day Moving Average 9.73
    50-Day Moving Average 11.09
    20-Day Moving Average 11.15
    10-Day Moving Average 11.38
    Average True Range 1.25
    RSI (14) 21.26
    ADX 26.69
    +DI 14.57
    -DI 53.30
    Chandelier Exit (Long, 3 ATRs) 9.76
    Chandelier Exit (Short, 3 ATRs) 7.78
    Upper Bollinger Bands 14.87
    Lower Bollinger Band 7.43
    Percent B (%b) -0.44
    BandWidth 66.73
    MACD Line -0.31
    MACD Signal Line 0.17
    MACD Histogram -0.4751
    Fundamentals Value
    Market Cap 104.1 Million
    Num Shares 25.3 Million
    EPS -3.89
    Price-to-Earnings (P/E) Ratio -1.06
    Price-to-Sales 51.84
    Price-to-Book 4.01
    PEG Ratio -1.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.97
    Resistance 3 (R3) 6.14 5.69 5.66
    Resistance 2 (R2) 5.69 5.22 5.61 5.55
    Resistance 1 (R1) 4.91 4.93 4.69 4.74 5.45
    Pivot Point 4.46 4.46 4.35 4.38 4.46
    Support 1 (S1) 3.68 3.99 3.46 3.51 2.79
    Support 2 (S2) 3.23 3.70 3.15 2.69
    Support 3 (S3) 2.45 3.23 2.58
    Support 4 (S4) 2.28